How Cisplatin and Oxaliplatin Affect Cancer Cells
Author Information
Author(s): Nehmé A, Baskaran R, Nebel S, Fink D, Howell S B, Wang J Y J, Christen R D
Primary Institution: Department of Medicine and the Cancer Center, University of California
Hypothesis
The study investigates how loss of DNA mismatch repair affects the activation of signaling pathways by cisplatin and oxaliplatin.
Conclusion
Cisplatin activates specific signaling pathways in DNA mismatch repair-proficient cells, while oxaliplatin does not activate these pathways in either proficient or deficient cells.
Supporting Evidence
- Cisplatin activates JNK kinase more efficiently in DNA mismatch repair-proficient cells.
- The c-Abl response to cisplatin is absent in DNA mismatch repair-deficient cells.
- No activation of JNK or c-Abl kinases was detected in response to oxaliplatin.
Takeaway
Cisplatin works differently than oxaliplatin in cancer cells, and the body's repair system helps detect damage from cisplatin but not from oxaliplatin.
Methodology
The study compared the activation of JNK and c-Abl pathways in cells with and without DNA mismatch repair when exposed to cisplatin and oxaliplatin.
Statistical Information
Confidence Interval
5.7 ± 1.5 (s.d.)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website